Ng, Alvin Wei Tian http://orcid.org/0000-0003-4672-0815
Contino, Gianmarco
Killcoyne, Sarah
Devonshire, Ginny http://orcid.org/0000-0002-1408-8176
Hsu, Ray
Abbas, Sujath
Su, Jing
Redmond, Aisling M.
Weaver, Jamie M. J.
Eldridge, Matthew D. http://orcid.org/0000-0002-5799-8911
Tavaré, Simon
Grehan, Nicola
Nutzinger, Barbara
Fidziukiewicz, Elwira
Freeman, Adam
Smyth, Elizabeth C.
O’Donovan, Maria
Miremadi, Ahmad
Malhotra, Shalini
Tripathi, Monika
Cheah, Calvin
Coles, Hannah
Flint, Connor
Eldridge, Matthew
Secrier, Maria
Jammula, Sriganesh
Davies, Jim
Crichton, Charles
Carroll, Nick
Hardwick, Richard H.
Safranek, Peter
Hindmarsh, Andrew
Sujendran, Vijayendran
Hayes, Stephen J.
Ang, Yeng
Sharrocks, Andrew
Preston, Shaun R.
Bagwan, Izhar
Save, Vicki
Skipworth, Richard J. E.
Hupp, Ted R.
O’Neill, J. Robert
Tucker, Olga
Beggs, Andrew
Taniere, Philippe
Puig, Sonia
Underwood, Timothy J.
Walker, Robert C.
Grace, Ben L.
Lagergren, Jesper
Gossage, James
Davies, Andrew
Chang, Fuju
Mahadeva, Ula
Goh, Vicky
Ciccarelli, Francesca D.
Sanders, Grant
Berrisford, Richard
Chan, David
Cheong, Ed
Kumar, Bhaskar
Sreedharan, L.
Parsons, Simon L.
Soomro, Irshad
Kaye, Philip
Saunders, John
Lovat, Laurence
Haidry, Rehan
Scott, Michael
Sothi, Sharmila
Lishman, Suzy
Hanna, George B.
Peters, Christopher J.
Moorthy, Krishna
Grabowska, Anna
Turkington, Richard
McManus, Damian
Coleman, Helen
Petty, Russell D.
Bartlett, Freddie
Edwards, Paul A. W. http://orcid.org/0000-0002-4789-3374
Fitzgerald, Rebecca C. http://orcid.org/0000-0002-3434-3568
,
Funding for this research was provided by:
DH | National Institute for Health Research (BRC-1215-20014)
RCUK | Medical Research Council (RG84369)
Cancer Research UK (RG66287, RG81771/84119)
Article History
Received: 7 September 2021
Accepted: 25 February 2022
First Online: 8 April 2022
Competing interests
: R.C.F. has devised an early detection technology called Cytosponge, this device technology and the associated TFF3 biomarker are licensed to Covidien GI solutions (now owned by Medtronic) by the Medical Research Council. R.C.F. and M.O. are named inventors on patents pertaining to the Cytosponge and associated technology. R.C.F. is a shareholder of Cyted Ltd., a company working on early detection technology. R.C.F. has received consulting and/or speaker fees from Medtronic, Roche and Bristol Myers Squibb. The other authors declare no competing interests.